How to find a needle in a haystack: a systematic review on targeting KRAS wild-type pancreatic cancer.
Antoine MouawadSofia HabibMarc BoutrosFouad AttiehHampig Raphaël KouriePublished in: Future oncology (London, England) (2024)
Aim: Pancreatic adenocarcinoma is a very aggressive type of cancer, in which targeted therapies have not yet been fully utilized. KRAS wild-type pancreatic adenocarcinoma tumors are associated with different genomic alterations in comparison to KRAS mutated pancreatic adenocarcinoma. Objective: This systematic review aims to provide a one-stop summary of all these alterations, their proposed targeted treatment and their effect on disease progression. Methods: An electronic search strategy was elaborated in the PubMed database between 2020 and January 2024. Results: 21 studies were included, and we found that the most frequent targetable genomic alterations in KRAS wild-type pancreatic adenocarcinoma were BRAF , EGFR , FGFR , MSI-H/dMMR , Her2/ERBB2 amplification, BRCA1/2 and other HRDs, and gene fusions like ALK , NTRK and NRG1 .
Keyphrases
- wild type
- systematic review
- copy number
- small cell lung cancer
- tyrosine kinase
- cancer therapy
- epidermal growth factor receptor
- papillary thyroid
- meta analyses
- genome wide
- advanced non small cell lung cancer
- squamous cell carcinoma
- randomized controlled trial
- emergency department
- dna methylation
- transcription factor
- combination therapy
- young adults